Immucell Corp. ICCC
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 1987 · data as of November 13, 2026
Immucell Corp. (ICCC) is a healthcare company listed in the US with a market value of about $98M. In the twelve months to September 30, 2026 it had revenue of $33M and net income of $2M, a net margin of 5.7%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (1/5).
Key numbers: a P/E of 56.6, a price to free cash flow of 18.1, 5-year revenue growth of 12% a year, a 5-year average ROIC of -2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.
About Immucell
Immucell is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 1987. Revenue went from $8M in 2014 to $28M in 2025, growth of about 12.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 17% over three years (dilution for shareholders). It spends 11% of revenue on research and development.
Score: 2.0 / 5
Checks passed
- P/FCF below 20
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33M | $28M | $26M | $17M | $19M | $19M | $15M | $14M | $11M | $10M | $10M |
| Net income | $2M | -$1M | -$2M | -$6M | -$2M | -$78292 | -$1M | -$1M | -$2M | -$168147 | $508448 |
| Free cash flow | $5M | $1M | -$107822 | -$7M | -$6M | -$2M | -$3M | -$1M | -$2M | -$17M | -$4M |
| EPS (diluted) | $0.19 | $-0.12 | $-0.26 | $-0.75 | $-0.32 | $-0.01 | $-0.14 | $-0.19 | $-0.42 | $-0.03 | $0.12 |
| Net margin | 5.7% | -3.8% | -8.1% | -33.1% | -13.4% | -0.4% | -6.7% | -9.4% | -21.1% | -1.6% | 5.3% |
| ROIC | — | 3.2% | -3.0% | -9.0% | -3.6% | 0.6% | -3.5% | -2.0% | -3.7% | -0.6% | 3.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Immucell’s P/E ratio?
About 56.6, based on the last twelve months of diluted earnings per share.
Is Immucell stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Immucell pay a dividend?
Not currently.
Is Immucell a good stock to buy?
We do not give buy or sell advice. Immucell scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.